Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $269 | $0 | $137 | $131 |
| SG&A Expenses | $269 | $0 | $137 | $131 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5 | $167 | -$1 | $0 |
| Operating Expenses | $263 | $167 | $137 | $131 |
| Operating Income | -$263 | -$167 | -$137 | -$131 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $405 | $688 | $569 | $1,456 |
| Pre-Tax Income | $142 | $521 | $432 | $1,325 |
| Tax Expense | -$405 | -$688 | -$474 | -$1,456 |
| Net Income | $547 | $1,210 | $905 | $2,781 |
| % Margin | – | – | – | – |
| EPS | 0.18 | 0.17 | 0.14 | 0.44 |
| % Growth | 5.9% | 21.4% | -68.2% | – |
| EPS Diluted | 0.18 | 0.09 | 0.067 | 0.21 |
| Weighted Avg Shares Out | 2,979 | 10,480 | 10,480 | 2,979 |
| Weighted Avg Shares Out Dil | 2,979 | 13,459 | 13,459 | 13,459 |
| Supplemental Information | – | – | – | – |
| Interest Income | $289 | $222 | $136 | $53 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $237 | -$342 | -$434 | -$1,338 |
| EBITDA | -$26 | -$509 | -$571 | -$1,469 |
| % Margin | – | – | – | – |